Medera Announces Independent Data Monitoring Committee (DMC) Recommends Continued Advancement of Lead HFpEF Gene Therapy Program

Published June 25, 2026 · Category: Markets

Overview

<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" />BOSTON, June 25, 2026 (GLOBE NEWSWIRE) -- Medera Inc. ("Medera"), a clinical-stage biotechnology company developing disease-modifying gene therapies for cardiovascular disease, today announced that the independent Data Monitoring Committee (DMC)...

Source

Originally published at markets.businessinsider.com.

Related Articles

• Identity theft victims face 'unconscionable' IRS delays, advocate says
• A Chevron exec says gas prices will come down — but not as fast as Trump wants
• Micron's earnings gave Wall Street exactly what the AI rally needed